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Abstract
Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after
invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lym-
phocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC.
Methods: We considered two patient series with TIL data: a multicentric retrospective series (n¼614) and the BIG 02-98 study
(n¼149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n¼159) and IDC
(n¼468) patients from the Nottingham series, as well as the CIBERSORT immune profiling of the ILC (n¼98) and IDC (n¼388)
METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)–positive/
human epidermal growth factor receptor 2 (HER2)–negative tumors. All statistical tests were two-sided.
Results: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change ¼ 0.79, 95% confidence interval
¼ 0.70 to 0.88, P < .001). In ILC, high TIL levels were associated with young age, lymph node involvement, and high
proliferative tumors. In the univariate analysis, high TIL levels were associated with worse prognosis in the retrospective and
BIG 02-98 lobular series, although they did not reach statistical significance in the latter. The Nottingham series revealed that
the levels of intratumoral but not total CD8þ were statistically significantly lower in ILC compared with IDC. Comparison of
the CIBERSORT profiles highlighted statistically significant differences in terms of immune composition.
Conclusions: This study shows differences between the immune infiltrates of ER-positive/HER2-negative ILC and IDC in terms
of prevalence, levels, localization, composition, and clinical associations.
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The presence and potential clinical value of tumor-infiltrating
lymphocytes (TILs) have been assessed in many studies.
Increased lymphocytic infiltration has been shown to be more
frequent in triple-negative and human epidermal growth factor
receptor 2 (HER2)–positive breast cancer and to be associated
with an increased pathological complete response rate after
neo-adjuvant chemotherapy, as well as with improved survival
after adjuvant chemotherapy in these subtypes (1–3). Given that
various methods have been used to quantify TILs in breast can-
cer, efforts to standardize their assessment were undertaken,
resulting in the first guidelines for scoring TILs (4). A recent pub-
lication also showed that the assessment of stromal TILs, those
present in the tumor stromal tissue, is more reproducible than
intratumoral TIL evaluation (5). A complementary approach to
evaluate immune infiltrates is to apply a deconvolution
algorithm to gene expression data, such as CIBERSORT, which
estimates the relative proportion of various immune cell types
(6–8).
Invasive lobular breast cancer (ILC) represents the second
most common histological subtype in breast cancer after inva-
sive breast carcinoma of no special type (NST), previously
known and further referred to as invasive ductal carcinoma
(IDC), and accounts for up to 15% of cases (9). These tumors gen-
erally express estrogen receptor (ER) and lack HER2 amplifica-
tion. Clinically, patients with ILC differ from those with IDC.
They tend to relapse later and present a different metastatic
pattern (9,10). Recently, The Cancer Genome Atlas (TCGA), the
RATHER consortium, METABRIC, and our group characterized
the genomic landscape of a large number of ILC tumors and
consistently demonstrated that ILC presents differences regard-
ing the frequency of alterations in several cancer genes
compared with IDC (11–14). Of potential relevance, TCGA and
RATHER consortia also identified an “immune-related” ILC tran-
scriptomic subtype. However, when comparing these immune
subtypes on the same data sets, it seems that they were not
identifying the same tumors, suggesting that their definition
should be further investigated (11,12).
While TILs in breast cancer continue to attract considerable
attention, to our knowledge, there are no previous reports inter-
rogating TILs in large cohorts of ILC. Using our multicentric ret-
rospective cohort of ILC (13), we aimed to evaluate the
distribution of TILs, correlate TIL levels with standard clinico-
pathological parameters, investigate their prognostic value, and
explore associations between TILs and transcriptomic features
and recurrent genomic alterations in ILC. We further aimed to
compare TILs between ER-positive/HER2-negative ILC and IDC
tumors in the BIG 02-98 study (15). Finally, going beyond TILs to
further enhance our understanding of the immune infiltrates in
ER-positive/HER2-negative ILC and IDC tumors, we compared
the proportion and localization of several immune subsets in
the Nottingham series (16–18) and the estimates of the propor-
tion of the different immune cell types provided by CIBERSORT
in the METABRIC and TCGA cohorts (7,11,19).
Methods
Patients and Samples
The retrospective multicentric series of primary ILC has already
been described (13). Supplementary Tables 1 and 2 (available
online) provide overview and patient-level information, respec-
tively, of the main clinical characteristics while Supplementary
Figure 1 (available online) reports the number of patients and
samples considered for each analysis. The comparison of TILs
in terms of prevalence and clinico-pathological associations be-
tween ER-positive/HER2-negative ILC (n¼ 149) and IDC (n¼ 807)
was assessed in the BIG 02-98 study (Supplementary Table 3,
available online) (15). From this study, we only considered those
patients whose tumor samples underwent central revision for
ER and HER2 (20). For the Nottingham series, we only considered
the ER-positive/HER2-negative ILC (n¼ 159) and IDC (n¼ 468)
cases (16–18). The patient and tumor characteristics from all in-
vestigated ER-positive/HER2-negative ILC and IDC cases are
reported in Supplementary Table 4 (available online). This proj-
ect has been approved by the ethics committee of the Institut
Jules Bordet (CE1726 and CE2560).
Assessment of Immune Infiltration
Stromal TIL, the percentage of tumor stromal area containing
TILs and hereinafter referred to as “TIL,” was independently
evaluated by three pathologists (GVE, GP, and RS) on hematoxy-
lin and eosin–stained slides of the retrospective ILC cohort
(n¼ 614) using the protocols described in Salgado et al. (4). To
evaluate the reliability of TIL assessments, the two-way random
intraclass correlation coefficient (ICC) was estimated (21). All
cases for which the discordance between at least two patholo-
gists reached greater than 15% were first independently re-
scored by all three pathologists and then reviewed together
until a consensus was reached. For each pathologist, consensus
values were used to recalibrate the other measurements
through Passing-Bablok regression (22). The log transformation
was applied to TIL values in order to stabilize variance and
achieve an approximately symmetric distribution according to
the measurement process (23). In the analyses, the arithmetic
mean over the three pathologists of the log values was used. In
the BIG 02-98 study, TILs were assessed previously by two path-
ologists, including RS, using the same method and the results
described in Loi et al. (15). For this study, we considered the ar-
ithmetic mean of the log values from the two pathologists.
Statistical Analysis
Univariate and multiple linear regression models of log-
transformed TIL percentage vs clinico-pathological and geno-
mic variables were fitted. Point estimates and 95% confidence
intervals of fold-change of TIL percentage were obtained. In the
retrospective ILC cohort and the BIG2-98 series, we used the pre-
viously reported survival end points, namely breast cancer–free
interval (BCFI) (13) and disease-free survival (DFS) (15), respec-
tively. The association between the survival end points and the
immune variables was evaluated using a Cox regression model
by considering TILs as either continuous or categorical values,
with or without adjustment for clinico-pathological variables.
Statistical significance was assessed using the Wald test. For
the comparison of the various immune markers in the
Nottingham series, we recurred to the proportional odds logistic
model extension of the Mann-Whitney test according to Harrell
(24) to adjust for histology, age, grade, axillary lymph node sta-
tus, and Ki67. CIBERSORT data from the METABRIC and TCGA
series were obtained from Ali et al. (n¼ 98 ILC and n¼ 388 IDC)
(7) and compared using the Wilcoxon rank sum test. All statisti-
cal tests were two-sided, and P values of less than .05 were
considered statistically significant. Whenever appropriate, we
applied correction for multiple testing using the
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Benjamini-Hochberg method (25). All analyses were performed
using R v3.4.1 (26).
Results
Distribution of TILs
The intraclass correlation coefficient between the three
pathologists for TIL evaluation on the 614 ILC cases from the
multicentric retrospective series was 0.71 (95% confidence inter-
val [CI] ¼ 0.65 to 0.76). ILC was characterized by low lymphocytic
infiltration, with a median percentage of TILs of 5% and an
interquartile range of 3% to 7% (Figure 1A). Fifteen percent of
the samples had more than 10% of TIL. We compared the
distribution of TILs in ER-positive/HER2-negative ILC with ER-
positive/HER2-negative IDC tumors from the BIG 02-98 study
(15) and observed that TIL counts were slightly but statistically
significantly lower in ILC compared with IDC (fold-change ¼
0.79, 95% CI ¼ 0.70 to 0.88, P < .001) (Figure 1B).
Association Between TILs and Clinico-Pathological
Variables
We investigated the association between TILs as a continuous
variable and the standard clinico-pathological variables. In the
retrospective series, we observed at the univariate level that
higher TIL values were associated with ER- and PR-negative sta-
tus, high proliferation status (20% Ki67), high grade, node-
positive status, and young age at diagnosis (Figure 2A;
Supplementary Table 5, available online). We further observed a
statistically significant increase and decrease of TILs for the
mixed nonclassic and the alveolar subtypes, respectively,
compared with the more common classic subtype. In the multi-
variable regression, a similar trend was detected for these varia-
bles, with the exception of tumor grade, for which the
association was no longer statistically significant. The associa-
tions between TILs and age, as well as Ki67 in all ILC patients
from BIG 02-98 (n¼ 204), were consistent with our results
(Supplementary Figure 2 and Supplementary Table 6, available
online). The association with lymph node involvement could
not be investigated as all patients included in this trial had posi-
tive lymph nodes. When restricting the analyses to the
ER-positive/HER2-positive ILC in our cohort (n¼ 555), we made
similar observations as in the global ILC population regarding
the association with high Ki67, node-positive status, and young
age at diagnosis (Figure 2A; Supplementary Table 7, available
online). We next used the TIL data collected in the BIG 02-98
trial to compare the associations in ER-positive/HER2-negative
IDC (n¼ 807) and ILC (n¼ 149). TILs were positively associated
with Ki67 both in IDC and ILC. However, the associations with
age and with grade were restricted to ILC and IDC, respectively
(Figure 2B; Supplementary Tables 8 and 9, available online).
Association Between TILs and Genomic Alterations
Genomic alterations with oncogenic potential (substitutions
and indels as previously defined (27) were available for 399
patients of the multicentric retrospective ILC series (13), leading
us to evaluate the association between TILs and the mutational
status of the 15 genes that were mutated in at least 2% of the
tumors. We observed statistically significantly lower TIL counts
in tumors harboring ERBB3 mutations and higher TIL counts in
tumors presenting somatic oncogenic TP53, ARID1A, and BRCA2
mutations compared with tumors that were not mutated in
those genes. KMT2C and PIK3CA mutated tumors were associ-
ated with higher TIL, although not statistically significantly
(Figure 3A; Supplementary Table 10, available online). All asso-
ciations remained statistically significant in multivariable mod-
els with standard clinico-pathological variables, with the
exception of BRCA2. We further investigated the association be-
tween TILs and copy number aberrations (CNAs) present in at
least 5% of the patients. Genome-wide copy number data were
available for 166 cases. We observed statistically significantly
higher TIL values in tumors with 8q24.23 loss (which included
PTK2) and 7p21.2 gains (ETV1), but statistically significantly
fewer TILs in tumors with 5q gains (Figure 3B; Supplementary
Table 11, available online).
Association Between TILs and Transcriptomic Features
In order to better understand the transcriptomic phenotype as-
sociated with infiltrated ILC tumors, we compared the gene ex-
pression profiles between ILC tumors with low (5%) and high
TIL levels (>10%), microarray gene expression data being
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Figure 1. Distribution of tumor-infiltrating lymphocytes (TILs). Histograms displaying the distribution of the TIL counts in all invasive lobular carcinoma (ILC) cases,
and only in the estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative ones (A), as well as the distribution of ER-positive/HER2-
negative ILC and invasive ductal carcinoma cases from the BIG 02-98 study (B). ER ¼ estrogen receptor; IDC ¼ invasive ductal carcinoma; ILC ¼ invasive lobular carci-
noma; TIL ¼ tumor-infiltrating lymphocyte.
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available for 117 tumors of the multicentric ILC cohort. Thirty-
three genes were overexpressed in the high-TIL group with a
fold-change of 1.2 or greater compared with the low-TIL group,
and a corrected P value of .05 or less. This list included, among
others, genes involved in cellular defense response
(GO:0006968; ITK, CXCL9, TRAT1, SH2D1A, and CCR6) and regula-
tion of antigen receptor–mediated signaling pathway
(GO:0050854; PRKCB, TRAT1, CCR7, UBASH3A) (Figure 3C). We
then computed a score based on these 33 genes and compared
it with existing immune and other gene expression signature
scores (28–37). We observed a strong correlation with several
previously reported immune expression signatures (Figure 3D),
suggesting that the immune infiltrates present in ILC might
share at least some similarities with the ones found in the
global breast cancer population.
Comparison of the Prevalence and Localization of
Different Immune Cell Types Between ER-Positive/
HER2-Negative ILC and IDC
We further aimed at extending our immune comparison between
ER-positive/HER2-negative ILC and IDC beyond TIL counts by in-
terrogating immuno-histochemical data on various immune
markers according to their localization (total staining or staining
restricted to the intratumoral, adjacent, or distant stromal com-
partments) in the Nottingham series (16–18), and the CIBERSORT
immune profiles in the METABRIC and TCGA data sets (7).
We compared the scores for CD3þ, CD8þ, CD20þ, CD68þ, and
FOXP3þ cells between the 159 ILC and 468 IDC samples from the
Nottingham series (Figure 4A). After adjusting for standard
clinico-pathological variables, we observed statistically signifi-
cantly lower levels in ILC compared with IDC regarding the adja-
cent stromal CD3þ, the intratumoral CD8þ, all measures of
CD68þ, and all except the intratumoral measures of FOXP3þ cells.
To complement this analysis, we compared the relative propor-
tion of the various immune cell types recognized by CIBERSORT
(7) and reported the statistically significant associations in
Supplementary Figure 4 (available online). Importantly, as in Ali
et al. (7), we considered only samples with a CIBERSORT P value
of less than .05, excluding samples without immune infiltration,
leaving 388 ER-positive/HER2-negative IDC samples to the 98 ER-
positive/HER2-negative ILC samples. The comparison revealed a
lower frequency of follicular helper and gamma delta T cells, as
well as M0, M1, and to a lesser extent M2 macrophages in ILC
compared with IDC, but a higher frequency of B memory cells,
monocytes, and CD8þ T cells. Unfortunately, these results do not
provide information regarding the localization of these different
immune cell types as CIBERSORT derives the immune subtyping
from bulk transcriptomic data.
Association Between TILs and Survival
Finally, we assessed the prognostic value of TILs in ILC. TILs
were initially considered a continuous variable for survival
A Univariate Multivariable
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Figure 2. Associations between tumor-infiltrating lymphocytes and clinico-pathological variables. Univariate and multivariable associations between tumor-infiltrat-
ing lymphocyte and clinico-pathological variables in all invasive lobular carcinoma (ILC) cases and only the estrogen receptor (ER)–positive/human epidermal growth
factor receptor 2 (HER2)–negative from our series (A), as well as from the ER-positive/HER2-negative ILC and invasive ductal carcinoma (B) from the BIG 02-98 study. ER
¼ estrogen receptor; IDC ¼ invasive ductal carcinoma; ILC ¼ invasive lobular carcinoma; TIL ¼ tumor-infiltrating lymphocyte.
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analysis, revealing that higher TILs were associated with a
worse prognosis in ILC in univariate (HR ¼ 1.22 for each 10%
increment, 95% CI ¼ 1.06 to 1.41, P ¼ .005) but not multivariable
analysis in the retrospective cohort (Supplementary Table 12,
available online). TILs were next considered a categorical vari-
able using the following groups, with the cut-points adapted
from the interquartile range rounded to the nearest multiple of
5: low (5%), intermediate (>5 and 10%), and high (>10%).
Both the high and intermediate groups were associated with
worse breast cancer–free interval (BCFI) compared with the low-
est TIL values (HRhigh vs low ¼ 1.84, 95% CI ¼ 1.22 to 2.78, P ¼ .004;
HRintermediate vs low ¼ 1.46, 95% CI ¼ 1.02 to 2.09, P ¼ .04) (Figure
5A). In multivariable analysis adjusting for the standard clinico-
pathological variables, the association between BCFI and TILs in
the group with high TIL values lost statistical significance
whereas the association remained statistically significant for
the group with intermediate TILs (Supplementary Table 13,
available online). Exploratory analyses in the ER-positive/HER2-
negative subgroup revealed a biologically consistent but statisti-
cally nonsignificant difference between the high and low groups
(HR ¼ 1.58, 95% CI ¼ 0.98 to 2.54, P ¼ .06) (Supplementary Table
14, available online), while no statistically significant difference
was observed between the TIL groups in the ER-negative and/or
HER2-positive subgroup (Figure 5B; Supplementary Figure 3A
and Supplementary Table 15, available online). We further
assessed the prognostic value of TILs in the BIG 02-98 series,
and, similar to the retrospective cohort, we observed that higher
TILs were associated with worse prognosis at the univariate
level, although not reaching statistical significance (Figure 5C;
Supplementary Table 16, available online). While the separation
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Figure 3. Associations between tumor-infiltrating lymphocytes (TILs), genomic and transcriptomic features in the retrospective invasive lobular carcinoma (ILC) cohort.
Univariate and multivariable associations between TIL and recurrently mutated genes (n¼399) (A) or recurrent copy number aberrations (n¼166) (B). Heatmap of the
genes statistically significantly associated with TILs at the transcriptomic level (C). Correlation matrix of the lobular immune gene expression signature (ILC TIL) with
published immune signatures (D). CNA ¼ copy number aberration; ILC ¼ invasive lobular carcinoma; TIL ¼ tumor-infiltrating lymphocyte.
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of the curves was visible for the ER-positive/HER2-negative ILC
subgroup (Figure 5D; Supplementary Table 17, available online),
the curves were completely superimposed for the ER-positive/
HER2-negative IDC (Supplementary Figure 3B and
Supplementary Table 18, available online).
Discussion
This work represents to our knowledge the most detailed and
comprehensive assessment of TILs using standardized, repro-
ducible protocols and the largest series of primary ILC samples
to date. We demonstrated that most ILCs are characterized by
low levels of TILs. The vast majority of ILC tumors (90%) are
ER-positive/HER2-negative, making our findings consistent with
previous reports showing that TILs are more prevalent in triple-
negative and HER2-positive breast cancer (15,38,39). Droeser
et al. reported lower levels of lymphocytic infiltrates in ILC
compared with IDC, based on the percentage of CD4þ
immunohistochemistry-stained cells; however, this compari-
son was flawed because they included all IDC and ILC tumors ir-
respective of ER and HER2 status (40). Our comparison of ER-
positive/HER2-negative ILC and IDC in the BIG 02-98 study, how-
ever, confirmed the slight but statistically significant increase
in TILs in IDC, even after adjusting for clinico-pathological
variables.
Several important findings emerged when comparing the
associations between TILs, clinico-pathological variables, and
survival between ER-positive/HER2-negative ILC and IDC. First,
while high TIL levels were associated with high proliferation
status as defined by Ki67 in both histological subtypes, the asso-
ciation of young age and high grade with high TIL levels was
only seen in ILC and IDC, respectively. Second, the survival
analyses in our retrospective ILC cohort revealed that increased
TILs were associated with worse BCFI at the univariate level.
This was the case when TILs were assessed either as a continu-
ous or categorical variable. This observation was somehow con-
trasting to what has been reported in triple-negative and HER2-
positive breast cancer, where increased TILs were associated
with better prognosis (1,2). However, in the multivariable analy-
sis, TILs lost their prognostic value at the continuous level, al-
though in the categorical analysis, the group with intermediate
TIL values remained associated with worse prognosis compared
with the group with low TILs. This loss of prognostic associa-
tion, once adjusted for the standard clinico-pathological varia-
bles, might be explained by the association of TILs with poor
prognostic features. Of interest, in the BIG 02-98 study, we ob-
served at the univariate level that high TILs were associated
with worse prognosis in ILC, although without reaching statisti-
cal significance. Interestingly, in this study, TILs did not show
any association with survival in ER-positive/HER2-negative IDC.
When we compared the immuno-histochemical scores (to-
tal, intratumoral, adjacent stromal, and distant stromal) of the
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Figure 4. Comparison of the expression of various immune cell types between estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–nega-
tive invasive lobular carcinoma. Distribution of the expression of the various immune markers assessed by immunohistochemistry in the Nottingham cohort accord-
ing to the histology and their localization. For each comparison, the value in parentheses refers to the multivariable-adjusted P value from the proportional odds
logistic model extension of the Mann-Whitney test according to Harrell (24) with the following covariates: histological subtype, age, grade, axillary lymph node, and
Ki67 status. ER ¼ estrogen receptor; ILC ¼ invasive lobular carcinoma.
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CD3þ, CD4þ, CD8þ, CD68þ, and FOXP3þ cells on the Nottingham
series between these two main breast cancer histologies, we no-
ticed that while no difference was observed for total CD8þ lev-
els, intratumoral CD8þ levels were statistically significantly
lower in ER-positive/HER2-negative ILC compared with IDC,
with very rare ILC cases presenting with intratumoral CD8þ
cells, suggesting that ILC might present an immune-excluded
phenotype where immune cells are retained in the stroma,
therefore limiting cancer immunity. As tumors with intratu-
moral CD8þ cells have been associated with the best outcome
(41), ILC tumors with high TIL levels might be associated with a
worse prognosis because of the lack of intratumoral CD8þ cells.
While the initial transcriptomic comparison between the less
and highly infiltrated groups showed similarities with previ-
ously reported immune signatures, the CIBERSORT analyses
further revealed statistically significant differences in immune
composition between infiltrated ER-positive/HER2-negative IDC
and ILC tumors. Whether the strong underrepresentation of M1
macrophages or follicular helper T cells in ILC compared with
IDC could further explain our prognostic observations needs to
be further investigated.
A unique advantage of our retrospective cohort was the abil-
ity to investigate the association between genomic alterations
and TILs. Tumors presenting ARID1A, BRCA2, and TP53 muta-
tions, as well as 8q24.23 loss and 7p21.2 gains, were associated
with higher TIL counts. Although we could not find previous ev-
idence for the association of ARID1A mutations and TILs in
breast cancer, a study of hepatocellular carcinoma demon-
strated that hepatocyte-specific deficiency of ARID1A leads to
the infiltration of innate immune cells (42). Similarly, in
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Figure 5. Association between tumor-infiltrating lymphocytes (TILs) and survival. Kaplan-Meier curves displaying the estimated breast cancer–free interval probability
according to the TIL group (low: 5%, intermediate: >5 and 10%, high: >10%) in all invasive lobular carcinomas (ILCs) (A) and only the estrogen receptor (ER)–positive/
human epidermal growth factor receptor 2 (HER2)–negative ILC of the retrospective series (B). Kaplan-Meier curves displaying the estimated disease-free survival prob-
ability according to the TIL group in all ILCs (C) and the only the ER-positive/HER2-negative ILC (D) from the BIG 02-98 series. All statistical tests were two-sided. ER ¼
estrogen receptor; ILC ¼ invasive lobular carcinoma; TIL ¼ tumor-infiltrating lymphocyte.
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colorectal cancer, ARID1A mutations are known to be more fre-
quent in microsatellite-instable tumors, and these tumors are
also associated with higher immune expression scores (43). It
has to be noted, however, that ARID1A mutations were previ-
ously demonstrated to be enriched in ER-positive/HER2-
negative ILC (6%) compared with ER-positive/HER2-negative
IDC (<2%) (13). Regarding BRCA2, our observation is in line with
the study of Bane et al., who reported that BRCA2-mutated
tumors exhibited lymphocytic infiltration at the periphery of
the tumor (44). While TP53 mutations have been shown to be as-
sociated with higher levels of TILs in ovarian cancer (45), lym-
phocytic infiltration in basal-like breast cancer has only
recently been reported to be associated with the retention of
wild-type TP53 (46). While some evidence is now beginning to
accumulate pertaining to the clinical utility of mutation burden,
the role of TILs and genomic alterations as potential biomarkers
for immunotherapy needs to be further investigated.
We recognize that this study has limitations, which are
mainly due to its retrospective nature and the clinical and path-
ological heterogeneity of the cohorts that were analyzed.
Nevertheless, this study represents, to the best of our knowl-
edge, the largest study investigating immune infiltration in ILC.
To conclude, we have shown, in a large cohort and using a
standardized methodology for TIL assessment, that most ILCs
were characterized by generally low but variable levels of lym-
phocytic infiltration. We further demonstrated that higher TIL
levels were associated with worse prognosis in ILC, but only at
the univariate level. The association of TILs with outcome in
ER-positive/HER2-negative breast cancer patients should be fur-
ther investigated in additional large trials to understand
whether the association is limited to ILC or not, and whether
high lymphocytic infiltration could drive endocrine resistance
as previously suggested (47). We further highlighted several dif-
ferences in terms of immune composition and localization be-
tween ILC and IDC, suggestive of an immune-exclusion
phenotype. Finally, we showed that higher TIL levels were
found in association with specific mutations and copy number
alterations. Overall, these observations suggest that that im-
mune infiltration could play a different role in ILC compared
with IDC. Further research is needed to understand whether
and how immunomodulators could reestablish and promote
the antitumor immune response in ILC.
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